CJC-1295 + Ipamorelin: How the Growth Hormone Stack Works

Overview of Growth Hormone Secretagogues

Growth hormone secretagogues (GHS) are compounds that stimulate the pituitary gland to secrete growth hormone (GH) by acting on the hypothalamic-pituitary axis. CJC-1295 and Ipamorelin represent two distinct classes of GHS that operate through separate receptor pathways, making their combination a subject of significant research interest.

Understanding this system requires familiarity with the somatotropic axis: the hypothalamus releases growth hormone-releasing hormone (GHRH) and somatostatin (which inhibits GH release) in alternating pulses. GHRH travels to the anterior pituitary and stimulates somatotroph cells to secrete GH into circulation. GH then acts on peripheral tissues and stimulates the liver to produce IGF-1, which mediates many of GH's downstream effects.

⚠ For in-vitro laboratory and preclinical research use only. Not for human consumption. Research use must comply with applicable institutional guidelines.

CJC-1295 (No DAC): GHRH Receptor Pathway

Structure and Stability

Native GHRH (1-44) is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) and other serum proteases, with a plasma half-life of under 10 minutes. CJC-1295 No DAC (Modified GRF 1-29) addresses this through strategic amino acid substitutions at positions 2, 8, 15, and 27:

• •Position 2: Alanine → D-Alanine (DPP-IV resistance)
• •Position 8: Asparagine → Glutamine (deamidation resistance)
• •Position 15: Glycine → Alanine (protease resistance)
• •Position 27: Methionine → Leucine (oxidation resistance)

These modifications extend plasma half-life to approximately 30 minutes while preserving full receptor binding affinity for GHRHR.

Mechanism

CJC-1295 No DAC binds the GHRH receptor on pituitary somatotroph cells, activating Gs protein-coupled cAMP production. Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates transcription factors including CREB, ultimately driving GH gene expression and secretion.

Ipamorelin: GHS-R1a (Ghrelin Receptor) Pathway

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide classified as the first highly selective growth hormone secretagogue receptor agonist. Published in 1998 by Raun and colleagues, it was identified from screening of GHRP (growth hormone-releasing peptide) analogues for selective GH-releasing activity.

Selectivity Profile

The defining characteristic of ipamorelin versus earlier secretagogues (GHRP-2, GHRP-6, hexarelin) is its receptor selectivity:

This selectivity — robust GH stimulation without significant co-activation of the HPA axis — makes ipamorelin particularly useful in research protocols where investigators wish to study GH-specific effects without confounding cortisol or prolactin elevations.

Mechanism

Ipamorelin binds GHS-R1a (the ghrelin receptor) on pituitary somatotrophs. Unlike the Gs/cAMP pathway activated by CJC-1295, GHS-R1a signals through Gq (increasing intracellular calcium via IP3/DAG pathway) and Gi (inhibiting adenylyl cyclase). The calcium-dependent pathway triggers exocytosis of pre-formed GH secretory granules — providing rapid GH release complementary to the transcription-driven cAMP pathway stimulated by CJC-1295.

The Synergistic Research Rationale

The basis for combining CJC-1295 and ipamorelin is the dual receptor pathway model: stimulating both GHRHR (via CJC-1295) and GHS-R1a (via ipamorelin) simultaneously activates two distinct intracellular cascades that converge on somatotroph GH secretion.

Preclinical data demonstrates:

• •CJC-1295 alone: ~1.5–2× baseline GH pulse amplitude
• •Ipamorelin alone: ~1.5–2× baseline GH pulse amplitude
• •Combined: 3–5× baseline GH pulse amplitude

The amplification exceeds simple additive expectations, consistent with convergent signalling: calcium (from ipamorelin/GHS-R1a) and cAMP (from CJC-1295/GHRHR) interact at the level of protein kinase activation to produce supra-additive exocytosis of GH-containing secretory granules.

Additionally, ipamorelin acts on hypothalamic GHS-R1a to inhibit somatostatin release — removing the brake from GH secretion, while CJC-1295 simultaneously increases the accelerator. Research suggests this dual mechanism produces larger, more consistent GH pulses than either compound alone.

Published Research Data

CJC-1295 (Teichman et al., 2006 — Human)

• •First published human pharmacokinetic study of CJC-1295 with DAC
• •2–10× increase in GH peak levels vs baseline
• •Sustained IGF-1 elevation for up to 6 days post-dose
• •Linear pharmacokinetics across dose range 0.03–0.3 mg/kg
• •Well tolerated in healthy adult volunteers

Ipamorelin (Raun et al., 1998 — Preclinical)

• •First characterisation of ipamorelin selectivity profile
• •Demonstrated selective GH release without cortisol or prolactin elevation
• •Established dose-response relationship in rat pituitary cell models
• •Defined ipamorelin as the benchmark for GHS selectivity

Research Interest in 2026

Search volume data indicates CJC-1295 + ipamorelin has become the most queried growth hormone secretagogue research topic in 2026, with monthly search volume exceeding 60,000 globally — reflecting broad preclinical and clinical research interest. The combination is under investigation in models relating to:

• •GH pulsatility and IGF-1 axis regulation
• •Age-related decline in GH secretion (somatopause)
• •Body composition research in metabolic disease models
• •Recovery time in exercise physiology models

Disclaimer: All information is for educational purposes relating to laboratory and preclinical research. CJC-1295 and Ipamorelin are research compounds not approved for human therapeutic use.